Drug Profile
Research programme: cancer and fibrotic disease therapeutics - Celgene/PharmAria
Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator PharmAria
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Fibrosis
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Fibrosis in USA